Keyphrases
Adoptive Cell Therapy
9%
Antibody Concentration
9%
Antibody Targeting
9%
Antibody-dependent Cellular Cytotoxicity
54%
Antigen Escape
9%
Antigen Receptor
9%
Antigen Recognition
9%
Antigen Targeting
100%
Antitumor Activity
9%
Antitumor Effect
9%
B-cell Lymphoma
9%
Binding Affinity
9%
Cancer Relapse
9%
CD16A
27%
CD64
100%
Cell Therapy Product
9%
Circulating Levels
9%
Clinical Outcomes
9%
Cryopreserved
9%
Cytoplasmic Area
9%
Escape Variants
9%
Extracellular Region
9%
Fc Receptor
9%
FcRI
9%
Feeder Cells
9%
Fusion Protein
9%
High Affinity
100%
Human B Cells
9%
Human IgG
18%
IgG Receptors
100%
In Vivo Assay
9%
IncuCyte
9%
Induced Pluripotent Stem Cells (iPSCs)
100%
Interleukin
9%
Interleukin-15 (IL-15)
9%
K562
9%
Lymphoma
100%
Lymphoma Cells
9%
Multi-antigen
18%
Myeloid Cells
9%
Natural Cytotoxicity
9%
Natural Killer Cells
100%
New Tumor
9%
Peripheral Blood NK Cells
9%
Polymorphism
9%
Raji
9%
Repurposing
9%
Stem Cell-derived
100%
Suboptimal Conditions
9%
Targeting Antibodies
9%
Targeting Potential
9%
Therapeutic Monoclonal Antibody
9%
Therapeutic Potential
18%
Transmembrane
9%
Tumor Antigen
100%
Tumor Cell Death
9%
Tumor Targeting
9%
Tumor Xenograft Model
9%
Xenograft Mouse Model
9%
Immunology and Microbiology
Antibody Blood Level
10%
Antibody-Dependent Cell-Mediated Cytotoxicity
60%
Antigen Recognition
10%
Antineoplastic Activity
10%
B Cell
10%
Binding Affinity
10%
Cell Killing
10%
Cytokine
20%
Cytotoxicity
10%
Fc Receptor
100%
Feeder Cell
10%
Induced Pluripotent Stem Cell
100%
Interleukin 15
10%
Lymphoma Cell Line
10%
Monoclonal Antibody Therapy
10%
Mouse Model
10%
Myeloid
10%
Natural Killer Cell
100%
Tumor Antigen
100%
Tumor Cell
10%
Xenograft
20%